2023 World Conference on Lung Cancer (Posters)-EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes

EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to compare the treatment outcomes of second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who acquired resistance to first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) based on their EGFR mutation status. The study included 381 patients with EGFR-mutant advanced NSCLC who received second-line treatment after developing resistance to first-line EGFR TKIs. Among these patients, 209 had negative results for the T790M mutation and received second-line chemotherapy. The patients were divided into two groups: those with common EGFR mutations (exon 19 deletion and exon 21 L858R substitution) and those with uncommon EGFR mutations. <br /><br />The results showed that patients with common EGFR mutations had significantly longer progression-free survival (PFS) compared to those with uncommon EGFR mutations (4.57 vs. 2.57 months). However, there was no significant difference in overall survival (OS) between the two groups (12.53 vs. 9.70 months). Cox proportional hazard regression analysis confirmed that the presence of uncommon EGFR mutations was an independent prognostic factor for PFS, indicating that patients with uncommon EGFR mutations had poorer response to chemotherapy and shorter survival compared to those with common EGFR mutations. <br /><br />These findings suggest that patients with uncommon EGFR mutations have a higher unmet need for effective treatment strategies. Further research and development of new treatment approaches are necessary to improve outcomes for this subgroup of patients. This study highlights the importance of considering EGFR mutation subtypes in the management of metastatic NSCLC and the potential impact on treatment response and survival.

Asset Subtitle

Jeng Shiuan Tsai

Meta Tag

Speaker Jeng Shiuan Tsai

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

treatment outcomes

second-line chemotherapy

NSCLC

EGFR mutation status

progression-free survival

overall survival

EGFR mutations

chemotherapy response

uncommon EGFR mutations

metastatic NSCLC